Currently, anti-PD-1/PD-L1 therapy has been approved by FDA as adjuvant therapy for resected melanoma, and tumor PD-L1 expression was proposed as a potential biomarker for predicting response to anti-PD-1/PD-L1 therapy (13). This evidence concerns the gene CD274 and neoplasm.